# EDGAR Filing Document

**Accession Number:** 0001697862
**File Stem:** 0001104659-23-002245
**Filing Date:** 2023-1
**Character Count:** 25626
**Document Hash:** b03973faed903dda6df7bd1e52a36ce9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-002245.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001104659-23-002245

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 25

**CONFORMED PERIOD OF REPORT**: 20230109

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARGENX SE
- **CENTRAL INDEX KEY:** 0001697862
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38097
- **FILM NUMBER:** 23518078

**BUSINESS ADDRESS:**
- **STREET 1:** INDUSTRIEPARK ZQIJNAARDE 7
- **STREET 2:** BUILDING C B-9052
- **CITY:** ZWIJNAARDE
- **STATE:** C9
- **ZIP:** B-9052
- **BUSINESS PHONE:** 32 (9) 310 34 00

**MAIL ADDRESS:**
- **STREET 1:** INDUSTRIEPARK ZQIJNAARDE 7
- **STREET 2:** BUILDING C B-9052
- **CITY:** ZWIJNAARDE
- **STATE:** C9
- **ZIP:** B-9052

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** argenx N.V
- **DATE OF NAME CHANGE:** 20170210

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of January 2023**

**Commission File Number: 001-38097**

**ARGENX SE**

(Translation of registrant's name into English)

**Laarderhoogtweg 25**

**1101 EB Amsterdam, the Netherlands**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**argenx SE**

On January 9, 2023, argenx SE (the "<u>Company</u>") issued a press release and a presentation the Company intends to use at the 41<sup>st</sup> Annual J.P. Morgan Healthcare Conference being held from January 9-12, 2023, copies of which are filed hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

*The information contained in this Current Report on Form 6-K, including the Exhibits, is incorporated by reference into the Company's Registration Statements on [F-3 (File No. 333-258251)](https://www.sec.gov/Archives/edgar/data/1697862/000110465921097286/tm2123446-1_f3asr.htm) and S-8 (File Nos. [333-225375](https://www.sec.gov/Archives/edgar/data/1697862/000110465918037616/a18-14643_3s8.htm) and [333-258253](https://www.sec.gov/Archives/edgar/data/1697862/000110465921097298/tm2123453d1_s8.htm)).*

**EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](tm232678d1_ex99-1.htm) | [Press Release dated January 9, 2023](tm232678d1_ex99-1.htm) |
| [99.2](tm232678d1_ex99-2.htm) | [Investor Presentation, January 9, 2023](tm232678d1_ex99-2.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ARGENX SE** | **ARGENX SE** |
| Date: January 9, 2023 | By: | /s/ Hemamalini (Malini) Moorthy |
|  |  | Hemamalini (Malini) Moorthy |
|  |  | General Counsel |

---

## Exhibit 99.1

**Exhibit 99.1**

**argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline**

*Reported $402 million in preliminary\* full-year 2022 global net VYVGART sales*

*ADHERE topline results now expected in second quarter of 2023; Stage B enrollment has surpassed projected target of 130 patients*

*Registrational trial of efgartigimod in thyroid eye disease (TED) to start in 2023; additional proof-of-concept trials to start in ANCA-associated vasculitis and antibody mediated rejection (AMR)*

*Submission for marketing approval in Japan of VYVGART for immune thrombocytopenia (ITP) expected in mid-2023*

**Amsterdam, the Netherlands** – January 9, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its strategic priorities for 2023 and provided preliminary financial results for the full year 2022, including global net product sales of VYVGART<sup>®</sup> (efgartigimod alfa-fcab).

"We had a landmark year in 2022, marking our first as a fully integrated immunology company transforming the treatment paradigm of generalized myasthenia gravis, and one which will stand as only the very beginning of what we expect to achieve as an organization," said Tim Van Hauwermeiren, Chief Executive Officer, argenx. "Looking forward, we will be expanding our patient reach both geographically and through the anticipated U.S. approval and launch of subcutaneous efgartigimod in March. By the end of 2023, we will be active in 15 IgG- and complement-mediated autoimmune diseases as we work to uncover the full breadth of our differentiated pipeline with key data readouts from additional indications of efgartigimod, as well as ARGX-117 and ARGX-119."

**2023 Strategic Priorities**

argenx will focus on four strategic priorities in 2023 to drive sustained growth and value creation as part of its 'argenx 2025' vision and a path to profitability.

**Reach More Patients with VYVGART**

argenx is planning for multi-dimensional expansion to reach more patients with VYVGART, its first-in-class neonatal Fc receptor blocker. This includes generalized myasthenia gravis (gMG) patients through regulatory approvals in new regions and the launch of its subcutaneous (SC) product offering, as well as a new autoimmune indication with the VYVGART regulatory submission for ITP in Japan.

&nbsp;&nbsp;&nbsp;&nbsp;• Prescription
 Drug User Fee Act (PDUFA) target action date of March 20, 2023, for U.S. Food and
 Drug Administration approval decision on SC efgartigimod for gMG

&nbsp;&nbsp;&nbsp;&nbsp;• Regulatory
 approval decision on SC efgartigimod for gMG expected in EU in fourth quarter of 2023

&nbsp;&nbsp;&nbsp;&nbsp;• Submission
 for marketing approval of SC efgartigimod for gMG expected in Japan in first quarter of 2023

&nbsp;&nbsp;&nbsp;&nbsp;• Regulatory
 approval decisions of VYVGART for gMG expected in Canada in third quarter of 2023 and in
 China and Israel by end of 2023

&nbsp;&nbsp;&nbsp;&nbsp;• gMG
 launch in France, United Kingdom and Italy expected by year-end 2023 following review of
 respective reimbursement dossiers

&nbsp;&nbsp;&nbsp;&nbsp;• Submission
 for Japan marketing approval of VYVGART for ITP expected in mid-2023

**Pioneer Development of FcRn Class with New Clinical and Translational Data**

argenx aims to solidify its FcRn leadership by expanding the scope of IgG-mediated autoimmune diseases in development and further demonstrating the potential of FcRn blockade with three Phase 3 trial readouts, one proof-of-concept trial readout, and a commitment to a 'bedside-to-bench' translational biology effort. By the end of 2023, efgartigimod is expected to be approved, in regulatory review or in development in 13 severe autoimmune diseases.

&nbsp;&nbsp;&nbsp;&nbsp;• ADHERE:
 Topline data in chronic inflammatory demyelinating polyneuropathy (CIDP) now expected in
 second quarter of 2023; Stage B enrollment has surpassed the initial projected target of
 130 patients

&nbsp;&nbsp;&nbsp;&nbsp;• ADDRESS:
 Topline data in pemphigus expected in second half of 2023

&nbsp;&nbsp;&nbsp;&nbsp;• ADVANCE-SC:
 Topline data from SC trial in ITP expected in second half of 2023

&nbsp;&nbsp;&nbsp;&nbsp;• Proof-of-concept
 data in post-COVID-19 postural orthostatic tachycardia syndrome (PC-POTS) expected in fourth
 quarter of 2023

&nbsp;&nbsp;&nbsp;&nbsp;• Registrational
 trial to start in TED in fourth quarter of 2023

&nbsp;&nbsp;&nbsp;&nbsp;• Proof-of-concept
 trials to start in ANCA-associated vasculitis and AMR in kidney transplant in fourth quarter
 of 2023; AAV trial to be run through IQVIA collaboration

&nbsp;&nbsp;&nbsp;&nbsp;• Externally
 sponsored research studies to launch in IgG-mediated neuromuscular autoimmune diseases in
 2023

&nbsp;&nbsp;&nbsp;&nbsp;• Translational
 work ongoing to understand potential disease-modifying effect of FcRn mechanism

**Drive Earlier-Stage Immunology Opportunities Towards Clinical Proof-of-Concept**

Beyond efgartigimod, argenx is advancing a robust portfolio of innovative clinical programs, including ARGX-117 (C2 inhibitor) and ARGX-119 (muscle-specific kinase (MuSK) agonist). Both programs have the potential to be first-in-class opportunities for multiple severe autoimmune indications.

&nbsp;&nbsp;&nbsp;&nbsp;• ARDA:
 Interim data from proof-of-concept trial of ARGX-117 in multifocal motor neuropathy expected
 mid-2023

&nbsp;&nbsp;&nbsp;&nbsp;• Proof-of-concept
 trial of ARGX-117 expected to start following regulatory discussions for prevention of delayed
 graft function after kidney transplantation

&nbsp;&nbsp;&nbsp;&nbsp;• Dermatomyositis
 selected as third autoimmune indication for development of ARGX-117

&nbsp;&nbsp;&nbsp;&nbsp;• Phase
 1 dose-escalation trial of ARGX-119 in healthy volunteers to start in first quarter of 2023
 with subsequent Phase 1b trial to assess early signal detection in patients

**Build Immunology Innovation Ecosystem to Drive Long-Term Pipeline Growth**

argenx continues to invest in its discovery engine, the Immunology Innovation Program, to foster a robust innovation ecosystem and drive early-stage pipeline growth. argenx expects to nominate one new development candidate in 2023.

**Preliminary\* Fourth Quarter and Full Year 2022 Financial Results**

argenx also announced today preliminary\* global net VYVGART revenues for the fourth quarter and full-year 2022 of approximately $175 million and $402 million, respectively.

As of December 31, 2022, argenx had approximately $2.2 billion in cash, cash equivalents and current financial assets\*. Based on its current operating plans and a projected 2023 cash burn of approximately $500 million, argenx expects its existing cash, cash equivalents and current financial assets, together with anticipated future product revenues, to fund the company to profitability.

\* - The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in March 2023.

**41st Annual J.P. Morgan Healthcare Conference Presentation and Webcast**

Mr. Van Hauwermeiren will highlight these updates in a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference today, Monday, January 9, 2023, at 9:00 a.m. PT. The live webcast of the presentation may be accessed under Investors on the argenx website. A replay will be available for 30 days following the presentation.

**About argenx**

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan and the EU. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on <u>LinkedIn</u>, <u>Twitter</u>, and <u>Instagram</u>.

**Media:**

Kelsey Kirk

kkirk@argenx.com

**Investors:**

Beth DelGiacco

bdelgiacco@argenx.com

**Forward Looking Statements**

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "hope," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements argenx makes concerning its preliminary financial results for the full year 2022; its expectations of future profitability; its plans for geographic expansion; the anticipated launch of its subcutaneous (SC) product in the U.S.; the initiation, timing, progress and results of its anticipated clinical development, data readouts and regulatory milestones and plans; its strategic priorities, including the timing and outcome of regulatory filings and regulatory approvals, and anticipated expansions in generalized myasthenia gravis (gMG) and IgG-mediated autoimmune diseases; the potential of its innovative clinical programs; and the nomination of new development candidates. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.*

## Exhibit 99.2

**Exhibit 99.2**

![](tm232678d1_ex99-2img01.jpg)

J.P. Morgan Healthcare Conference January 2023

![](tm232678d1_ex99-2img02.jpg)

2 Forward Looking Statements This presentation has been prepared by argenx se (" argenx " or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all - inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third - party sources and our own internal estimates and r esearch. While we believe these third - party studies, publications, surveys and other data to be reliable as of the date of this presentation, we have not independently v eri fied, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third - party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this p res entation relating to or based on such internal estimates and research. Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward - looking statements . Examples of such forward - looking statements include those regarding preliminary financial results for the full year 2022 ; expectations of future profitability ; plans for geographic expansion ; the anticipated launch of argenx's subcutaneous ("SC") product in the U . S .; the initiation, timing, progress and results of our anticipated clinical development, data readouts and regulatory milestones and plans ; strategic priorities, including the timing and outcome of regulatory filings and regulatory approvals, and anticipated expansion in generalized myasthenia gravis (gMG) and IgG - mediated autoimmune diseases ; the potential of argenx's innovative clinical programs ; and the nomination of new development candidates . A further list and description of these risks, uncertainties and other risks can be found in argenx's U . S . Securities and Exchange Commission ("SEC") filings and reports, including in argenx's most recent annual report on Form 20 - F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC . Given these uncertainties, the reader is advised not to place any undue reliance on such forward - looking statements . These forward - looking statements speak only as of the date of publication of this presentation . argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward - looking statements, except as may be required by law . This presentation contains trademarks, trade names and service marks of other companies, which are the property of their resp ect ive owners.

![](tm232678d1_ex99-2img03.jpg)

We are on a bold mission Transforming the lives of patients with severe autoimmune disease through immunology i nnovation

![](tm232678d1_ex99-2img04.jpg)

Autoimmunity is Prime for REVOLUTION A pipeline of precision tools Redefining Autoimmune Diseases With Precision Medicine Approach Redefine our pipeline of autoimmune diseases as IgG - mediated or complement - driven Offer new targeted treatment modality in diseases where innovation is most needed

![](tm232678d1_ex99-2img05.jpg)

Redefining What 'Well - Controlled' Means for the Patient Achieve minimal symptom expression Reduce reliance on broad immunosuppressants Regain control of their lives, including professionally and socially Minimize treatment burden We want to transform gMG treatment for patients

![](tm232678d1_ex99-2img06.jpg)

Lead with Compassion for our Patients Drive Impact Through Innovation Pioneer with Our Science Build the Company We Want to Work For argenx 2025: A Leading, Sustainable Immunology Company …and gMG is just the beginning

![](tm232678d1_ex99-2img07.jpg)

2022: Transformed into an Integrated Immunology Company VYVGART launched in U.S., Japan & Germany Enabled appropriate access through value - based agreements 90% US POLICIES FAVORABLE Built scalable global supply chain LARGE SCALE CAPACITY TO HANDLE DEMAND Rapid HCP adoption 90% of KEY TARGETS REACHED in 2022 SUBMISSIONS IN 10+ COUNTRIES $21M $75M $131M $175M 1Q 2Q 3Q 4Q global product revenues in Year 1 More than 3,000 patients on VYVGART®

![](tm232678d1_ex99-2img08.jpg)

2022: Strengthened Efgartigimod Data Story 0 - 30 - 60 Baseline 1 2 3 4 5 6 7 8 10 Mean I gG reduction % IgG reduction (%) in all ADAPT - SC and ADAPT participants LS - Mean Platelet Count Change From Baseline (x10 9 /L) - 20 0 20 40 0 12 24 Week VYVGART PLACEBO Clear Clinical Benefit in ITP Disease - Modifying Potential of FcRn Blockade SC Noninferiority to IV

![](tm232678d1_ex99-2img09.jpg)

2022 : Broadened Scope of Efgartigimod Safety Database 1. Ulrichts P, et al. J Clin Invest . 2018;128(10):4372 - 4386. doi : 10.1172/JCI97911. Scope of Safety Database >1,300 clinical study subjects Molecular design yields unique interaction with FcRn and differentiated safety profile Post - marketing data confirm positive benefit/risk profile as established in clinical trials No reduction in albumin levels; no increase in lipid levels Cumulative exposure of >1,000 patient years Different dosing regimens (up to 19 cycles of 4 weekly doses; up to 2 years of weekly dosing) TEAEs consistent across >4 indications; typically mild to moderate Low discontinuation rates due to side effects in clinical studies to date 1 2 3

![](tm232678d1_ex99-2img010.jpg)

Reach more patients with VYVGART globally Pioneer FcRn class of medicines Broaden immunology pipeline Build out innovation ecosystem commercial clinical clinical discovery 2023: Key Drivers of our Path to Profitability

![](tm232678d1_ex99-2img011.jpg)

Reach More Patients with VYVGART Globally Geographic expansion Launch SC product offering Drive usage in earlier line patients Reach more patients with VYVGART globally commercial File for ITP in Japan Ongoing studies in new indications DRIVE GROWTH IN NEW PATIENT SEGMENTS DRIVE MULTI - DIMENSIONAL EXPANSION IN gMG

![](tm232678d1_ex99-2img012.jpg)

IgG Autoantibodies Serve as Unifying Biology Rationale for POC Indications DSG - 1 DSG - 3 AChR GPIIb /IIIa NF155 Contactin1 BP180 BP230 JO - 1 SRP HMGCR Mi - 2 MPO - ANCA PR3 - ANCA PLA2R GPCR Immune complexes TSHR THSd7A NELL1 ANA Ro/SSA La/SSB Pioneer FcRn class of medicines clinical MuSK LRP4 DSA

![](tm232678d1_ex99-2img013.jpg)

Pipeline - in - a - Product Indicates Significant Market Opportunity PC - POTS > 500K ANCA 105K TED 10 0K Sjogren's 330K Membranous Nephropathy 8 0K BP 52K gMG 65K ITP 57K Myositis 63K Pemphigus 19K CIDP 16K Lupus Nephritis 40 K AMR 8K clinical Patient numbers are U.S. prevalence from argenx market research

![](tm232678d1_ex99-2img014.jpg)

gMG 65K CIDP 16K BP\* 52K Membranous Nephropathy 80K TED 100K ANCA 105K AMR 8K PC - POTS >500K Sjogren's 330K Lupus Nephritis 40K Steady Cadence of Data Readouts Over Next Several Years APPROVED APPROVED/IN REVIEW 2023 DATA READOUTS 2023 DATA READOUTS 2024 DATA READOUTS 2024 DATA READOUTS 2025+ DATA READOUTS 2025+ DATA READOUTS Myositis\* 63K Pemphigus 19K ITP 57K Late Stage Proof - of - Concept clinical Patient numbers are U.S. prevalence from argenx market research \*GO/NO GO Decisions.

![](tm232678d1_ex99-2img015.jpg)

Optimal recycling pH and Ca2 + switch No effector function ARGX - 117: Targets C2 at Junction of Classical and Lectin Pathways 2024 DATA READOUTS Three Indications Selected Based on Biology Rationale 2024 DATA READOUTS ARGX - 117: Sweeping Antibody Broaden immunology pipeline clinical Indication selection starts with autoimmune diseases driven by classical and/or lectin pathway Phase 2 proof - of - concept trial underway in multifocal motor neuropathy (MMN) with interim data expected in mid - 2023 Phase 2 trials to start in delayed graft function and dermatomyositis

![](tm232678d1_ex99-2img016.jpg)

clinical ARGX - 117: Strong Translational Biology Rationale for C2 Blockade in MMN A - GM 1 antibody mediated complement attack on the Schwann cell membrane Significant disruption to the axo - glial junction and cytoplasmic paranodal loops resulting in conduction block – hall mark of MMN Campbell et al , 2022 Significant reduction of injury to paranodal proteins at the Nodes of Ranvier improves respiratory function in vivo Anti - GM1 Antibody Anti GM1 - Antibody Anti GM1 - Antibody Naïve Control C2 Inhibitor Anti GM1 - Antibody Naïve Control C2 Inhibitor

![](tm232678d1_ex99-2img017.jpg)

ARGX - 119: MuSK Agonist with Broad Potential in Neuromuscular Disease 10 dose cohorts 3 dose cohorts/4 weekly doses Congenital Myasthenic Syndrome (CMS) and MuSK MG First - in - Patient Single Ascending Dose (0.005mg/kg – 15mg/kg) Multiple Ascending Dose (0.3mg/kg – 2.5mg/kg) First - in - patient trial in CMS and MuSK MG to serve as proof of biology Translational work ongoing in amyotrophic lateral sclerosis First - in - Human Phase 1 Healthy Volunteer Study Broaden immunology pipeline clinical

![](tm232678d1_ex99-2img018.jpg)

Neuromuscular Neuromuscular Neuromuscular Neuromuscular Neuromuscular Neuromuscular Neuromuscular Neuromuscular Positioned for Long - term Franchise Growth Hematology and Rheumatology Neurology Dermatology Nephrology gMG , CIDP, Myositis, TED, MMN, CMS, Musk MG, ALS ITP, Sjogren's, POTS, Anca Vasculitis Pemphigus, Bullous Pemphigoid, Dermatomyositis Membranous Nephropathy, Lupus Nephritis, AMR, DGF

![](tm232678d1_ex99-2img019.jpg)

Innovation Ecosystem Build out innovation ecosystem discovery

![](tm232678d1_ex99-2img020.jpg)

Positioned for a Catalyst - Rich 2023 VYVGART gMG Approval in China VYVGART gMG Approval in Canada VYVGART gMG Launch in France, UK, Italy SC efgartigimod gMG Approval in US SC efgartigimod gMG Approval in EU SC efgartigimod gMG Submission in Japan VYVGART ITP Submission in Japan 2Q 2023 2H 2023 2H 2023 4Q 2023 Additional pipeline • ARGX - 117: ARDA MMN interim results • ARGX - 117: Initiate DGF POC study • ARGX - 119: Initiate Phase 1 study Efgartigimod • ADHERE data in CIDP • ADDRESS data in Pemphigus • ADVANCE (SC) data in ITP • POC data in Post - COVID POTS • Initiate registrational trial in TED • Initiate POC studies in AAV and AMR Commercial Clinical 4Q 2023 4Q 2023 Mid - 2023 1Q 2023 2H 2023 YE 2023 3Q 2023 YE 2023 Mid - 2023 March 20, 2023 1Q 2023 4Q 2023

![](tm232678d1_ex99-2img021.jpg)

Our mission continues… Humility Innovation Excellence Co - Creation Empowerment

![](tm232678d1_ex99-2img022.jpg)

Program Indication Preclinical Phase 1 Proof of Concept Registrational Commercial VYVGART T gMG (IV) Efgartigimod gMG (SC) CIDP Myositis Thyroid Eye Disease ITP (IV) ITP (SC) COVID - 19 Mediated POTS Sjogren's Syndrome Anca Vasculitis Pemphigus Bullous Pemphigoid Membranous Nephropathy Lupus Nephritis Antibody Mediated Rejection ARGX - 117 Multifocal Motor Neuropathy Dermatomyositis Delayed Graft Function After Kidney Transplant ARGX - 119 Neuromuscular Indications NEUROLOGY HEMATOLOGY AND RHEUMATOLOGY DERMATOLOGY NEPHROLOGY Key: Breadth and Depth Within Autoimmune Pipeline